Open Access Highly Accessed Research

Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells

Zhitu Zhu1,4*, Enze Li1, Yangyang Liu1, Yu Gao1, Hongzhi Sun1, Guangyou Ma1, Zhenghua Wang1, Xiaomei Liu1, Qingjun Wang1, Xiujuan Qu2, Yunpeng Liu2 and Yunlong Yu3

Author Affiliations

1 Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning, 121001, China

2 Department of Oncology, The First Affiliated Hospital of Chinese Medical University, No 155, Nanjingbei Street, Heping District, Shenyang, Liaoning, 11001, China

3 Department of Oncology, China National Offshore Oil Corporation Hospital, No 10, Shiyou Rd, Tanggu District, Tianjing, 300452, China

4 Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, No 2, Wuduan Rengmin Street, Jinzhou, 121001, China

For all author emails, please log on.

World Journal of Surgical Oncology 2012, 10:228 doi:10.1186/1477-7819-10-228

Published: 30 October 2012

Abstract

Background

The purpose of the research is to investigate the roles of Jak-STAT3 signaling pathway in bufalin-induced apoptosis in colon cancer SW620 cells.

Methods

The inhibitory effects of bufalin on cell proliferation were determined by MTT (Methyl thiazolyltetrazolium) assay. The morphological changes of cells were measured by Wright-Giemsa staining. The cell cycle arrest and apoptosis were tested by flow cytometry analysis. Western Blot was used to determine the protein expression of the apoptosis inhibitors livin and caspase-3, the apoptosis-related proteins Bax and Bcl-2, as well as the key protein kinases in the Jak-stat3 signaling pathway, stat3 and p-stat3.

Results

(1) Bufalin inhibited the proliferation of SW620 cells. IC50 at 24 h, 48 h and 72 h were 76.72 ± 6.21 nmol/L, 34.05 ± 4.21 nmol/L and 16.7 ± 6.37 nmol/L. (2) Bufalin induced SW620 cell cycle arrest and apoptosis, indicated by the appearance of apoptotic bodies; (3) The results from flow cytometry demonstrated that there was cell cycle G2/M phase arrest in 20 nmol/L bufalin treatment group (36.29 ± 2.11% vs 18.39 ± 1.74%, P<0.01); there was a sub-diploid apoptosis peak in 80 nmol/L bufalin treatment group (19.69 ± 1.63% vs 0.99 ± 0.23%, P <0.01). The apoptosis rate was 34.63 ± 2.57% (vs 19.69 ± 1.63%, P = 0.002) in JAK kinase inhibitor AG490 plus bufalin treatment group. (4) During the process of bufalin-induced apoptosis in SW620 cells, transient activation of p-stat3 inhibited the activation of stat3, up-regulated Bax expression, down-regulated livin and Bcl-2 expression (P<0.01), and activated caspase-3. Inhibition of Jak-stat3 signaling pathway by pre-treatment with AG490 significantly enhanced the bufalin-induced apoptosis (P<0.01), further up-regulated Bax protein expression, down-regulated livin and Bcl-2 protein expression and enhanced caspase-3 activation.

Conclusions

Bufalin not only inhibited the growth of colon cancer SW620 cells, but also induced apoptosis of SW620 cells. Activation of caspase-3, up-regulation of Bax, down-regulation of livin and Bcl-2, as well as inhibition of Jak-stat3 signaling pathway might be the important mechanisms for the bufalin-induced apoptosis.

Keywords:
Colon cancer; Jak-stat3; Bufalin; Livin; Caspase; M-phase arrest; Apoptosis